CLEC1B and Venous thrombosis: They suppressed human atherosclerotic plaque-induced thrombus formation, mainly by inhibiting platelet glycoprotein VI (GPVI)-signaling [8,9], and venous thrombosis by inhibiting platelet CLEC-2 signaling [10,11].